皮尔芬尼:眼科治疗中一个有前途的药物
Amol Chhatrapati Bisen1,2, Sristi Agrawal1,2, Ramakrishna Rayiti1,2
1Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.
Chemistry & biodiversity
|February 1, 2024
概括
皮尔芬尼原本用于肺纤维化,在治疗角膜纤维化和糖尿病视网膜病变等眼睛疾病方面表现有前途. 这篇评论强调了它在重塑眼部护理和减少眼部炎症和创伤方面的潜力.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮尔芬尼是治疗异常性肺纤维化的一种成熟治疗方法.
- 新兴研究表明,皮尔芬尼具有抗纤维素,抗炎和抗增殖性质.
- 这些特性表明,除了肺部疾病之外,还有潜在的治疗应用.
研究的目的:
- 审查有关皮尔芬尼在各种眼部疾病中的疗效的现有文献.
- 探索皮尔芬尼可能有益于眼睛愈合的机制.
- 评估皮尔芬尼在治疗角膜纤维化,炎症和创伤方面的潜在作用.
主要方法:
- 在数据库 (如PubMed,Scopus) 中进行系统的文献搜索.
- 包括在动物模型和人类眼病临床试验中研究皮尔芬尼的研究.
- 对皮尔芬尼对眼睛组织纤维化,炎症和细胞增殖的影响的数据分析.
主要成果:
- 在临床前模型中,皮尔芬尼在减轻角膜纤维化和炎症方面表现出有效性.
- 有证据表明,皮尔费尼在糖尿病视网膜病变和与年龄相关的黄斑变性等疾病中具有益处.
- 研究表明,皮尔芬尼在治疗术后玻璃眼和眼睛创伤方面具有积极的结果.
结论:
- 皮尔芬尼在一系列眼科疾病中表现出显著的治疗潜力.
- 它的多方面的作用使其成为新眼科治疗的有希望的候选人.
- 需要进一步的临床研究来充分确定皮尔芬尼在眼睛护理中的作用.
相关概念视频
01:27Open Angle Glaucoma: Treatment
452
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
452
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
182
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
182